

Dear Parent/Guardian,

**Covid 19 immunisation during this Autumn/Winter campaign 2024**

The Autumn/Winter immunisation campaign 2024 concludes in the next few weeks. If your child is eligible due to their medical history (see below), they may have an increased risk of complications if they acquire Covid 19 disease.

Immunisation offers your child the greatest protection against Covid 19 as we move into winter. Risk groups include those with neurodisability and severe/profound learning disabilities.

Over the next few weeks, we are holding immunisation clinics for Covid 19 at Birmingham Children's Hospital.

To book an appointment please contact the bookings team either via email at [BSOLVaccinationBooking@uhb.nhs.uk](mailto:BSOLVaccinationBooking@uhb.nhs.uk) or via telephone on 0121 371 8445

If you have any questions or require more information, please contact the bookings team who will be happy to assist.

Kindest regards,

Fiona Etheridge RGN RSCN  
Senior Nurse  
BSOL vaccination programme

**Table 4: Clinical risk groups for individuals aged under 16 years**

Chronic respiratory disease	Including those with poorly controlled asthma <sup>1</sup> that requires continuous or repeated use of systemic steroids or with previous exacerbations requiring hospital admission, cystic fibrosis, ciliary dyskinesias and bronchopulmonary dysplasia
Chronic heart conditions	Haemodynamically significant congenital and acquired heart disease, or less severe heart disease with other co-morbidity. This includes: <ul style="list-style-type: none"> <li>• single ventricle patients or those palliated with a Fontan (Total Cavopulmonary Connection) circulation</li> <li>• those with chronic cyanosis (oxygen saturations &lt;85% persistently)</li> <li>• patients with cardiomyopathy requiring medication</li> <li>• patients with congenital heart disease on medication to improve heart function</li> <li>• patients with pulmonary hypertension (high blood pressure in the lungs) requiring medication</li> </ul>
Chronic conditions of the kidney, liver or digestive system	Including those associated with congenital malformations of the organs, metabolic disorders and neoplasms, and conditions such as severe gastro-oesophageal reflux that may predispose to respiratory infection
Chronic neurological disease	Conditions in which respiratory function may be compromised; this includes those with: <ul style="list-style-type: none"> <li>• neuro-disability and/or neuromuscular disease that may occur as a result of conditions such as cerebral palsy, autism, epilepsy and muscular dystrophy</li> <li>• hereditary and degenerative disease of the nervous system or muscles, other conditions associated with hypoventilation</li> <li>• severe or profound and multiple learning disabilities (PMLD), Down's syndrome, including all those on the learning disability register</li> <li>• neoplasm of the brain</li> </ul>
Endocrine disorders	Including diabetes mellitus, Addison's and hypopituitary syndrome
Immunosuppression	Immunosuppression due to disease or treatment, including: <ul style="list-style-type: none"> <li>• those undergoing chemotherapy or radiotherapy, solid organ transplant recipients, bone marrow or stem cell transplant recipients</li> <li>• genetic disorders affecting the immune system (e.g. deficiencies of IRAK-4 or NEMO, complement disorder, SCID)</li> <li>• those with haematological malignancy, including leukaemia and lymphoma</li> <li>• those receiving immunosuppressive or immunomodulating biological therapy</li> <li>• those treated with or likely to be treated with high or moderate dose corticosteroids</li> <li>• those receiving any dose of non-biological oral immune modulating drugs e.g. methotrexate, azathioprine, 6-mercaptopurine or mycophenolate</li> <li>• those with auto-immune diseases who may require long term immunosuppressive treatments</li> </ul> <p>Children who are about to receive planned immunosuppressive therapy should be considered for vaccination prior to commencing therapy.</p>
Asplenia or dysfunction of the spleen	Including hereditary spherocytosis, homozygous sickle cell disease and thalassaemia major
Serious genetic abnormalities that affect a number of systems	Including mitochondrial disease and chromosomal abnormalities
Pregnancy	All stages (first, second and third trimesters)

<sup>1</sup> Poorly controlled asthma is defined as:

- ≥2 courses of oral corticosteroids in the preceding 24 months OR
- on maintenance oral corticosteroids OR
- ≥1 hospital admission for asthma in the preceding 24 months

<https://www.brit-thoracic.org.uk/covid-19/covid-19-information-for-the-respiratory-community/#jcvi-advice-on-covid-19-vaccination-for-children-aged-12-15-years-in-clinical-at-risk-groups>